Compare AVD & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AVD | ACET |
|---|---|---|
| Founded | 1969 | 1947 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Agricultural Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 74.1M | 77.3M |
| IPO Year | 1995 | 2017 |
| Metric | AVD | ACET |
|---|---|---|
| Price | $2.64 | $8.32 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $12.00 | ★ $48.33 |
| AVG Volume (30 Days) | ★ 385.4K | 73.6K |
| Earning Date | 03-16-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 61.11 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $515,114,000.00 | N/A |
| Revenue This Year | $8.82 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.05 | $0.46 |
| 52 Week High | $5.92 | $9.47 |
| Indicator | AVD | ACET |
|---|---|---|
| Relative Strength Index (RSI) | 47.84 | 54.49 |
| Support Level | $2.37 | $7.02 |
| Resistance Level | $2.66 | $8.34 |
| Average True Range (ATR) | 0.24 | 0.43 |
| MACD | -0.01 | 0.05 |
| Stochastic Oscillator | 31.76 | 88.03 |
American Vanguard Corp is a United States-based diversified specialty and agricultural products company. The company is a manufacturer of specialty solutions that develops and markets safe synthetic, biological, and biorational products for agricultural, commercial, and consumer uses. These chemicals include insecticides, fungicides, herbicides, molluscicides, growth regulators, and soil fumigants, which are marketed in liquid, powder, and granular forms.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. It is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. The company's main product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, and is being developed for the potential treatment of autoimmune diseases. Additionally, it is pursuing ADI-212, a next-generation gene-edited and armored clinical candidate designed to target prostate-specific membrane antigen (PSMA).